News
Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results